Private Capital Advisors’s Immunic IMUX Stock Holding History

Private Capital Advisors’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-250	Closed	-$28K	–	94
2018 Q3	$28K	Buy	+250	New	+$653K	0.01%	96

Other funds holding IMUX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Private Capital Advisors's IMUX Position: Q4 2018 in Review

Private Capital Advisors sold out of Immunic (IMUX) in Q4 2018, closing a stake of 250 shares — an estimated $28K sold.

Private Capital Advisors first reported a position in IMUX in Q3 2018 and held it in 1 quarter. The position peaked at $28K in Q3 2018. 47 funds tracked by Wall St. Rank hold IMUX as of Q4 2018.

Private Capital Advisors reported no remaining Immunic position as of Q4 2018 after selling out during the quarter.
Private Capital Advisors sold 250 Immunic shares in Q4 2018, an estimated $28K.
Private Capital Advisors first reported a position in Immunic in Q3 2018 and held it in 1 quarter.
Private Capital Advisors's Immunic position peaked at $28K in Q3 2018.
47 funds tracked by Wall St. Rank held Immunic as of Q4 2018.

Based on Private Capital Advisors's 13F filing for Q4 2018, filed 14 Jan 2019.